Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues

Fischer, Romy; Debbabi, Hajer; Blais, Anne; Dubarry, M; Rautureau, M; Boyaka, Prosper N.; Tomé, Daniel

doi:10.1016/j.intimp.2007.05.019

Cited by 80 publications

(76 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LRP1 is also known to be a key receptor mediating the uptake of chylomicron remnants, which carry dietary lipids into the liver. It has been reported that bLF is transported into circulation from the intestine via the lymphatic pathway in rats 19 and orally administered bLF was detected in many mouse tissues, including the serum and liver 20 .…”

Section: Discussionmentioning

confidence: 99%

Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice

et al. 2013

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice

et al. 2013

View full text Add to dashboard Cite

“…LF receptors have been identified in the gastrointestinal tract, on leukocytes and macrophages, platelets, and on bacteria. The BLF is transferred from the intestine into peripheral blood in a form with intact molecular weight (80 kDa) and is localized within 10 to 20 min after oral administration in the liver, kidneys, gall bladder, spleen, and brain [21].…”

Section: Compositionmentioning

confidence: 99%

Lactoferrin and Its Role in Neonatology: A Review Article

Sharma¹

2015

JPNC

View full text Add to dashboard Cite

Lactoferrin (LF) is a glycoprotein, which is present in milk of mammals. It has been proven to plays a very important role in innate immune host defences. It is well known that Neonatal sepsis and necrotizing enterocolitis (NEC) are responsible for significant morbidity and mortality in the new-born, especially in VLBW (1500 grams at birth) infants. The ill effects of sepsis and NEC persist in spite of appropriate and effective antibiotic therapy and have been associated with poor long term outcome. In the few recent trials which have been conducted around the globe, in field of neonatology, role of LF in prevention of neonatal sepsis and NEC has been strengthened. Furthermore many trials are underway and only future may provide a definite answer of LF role in sepsis and NEC. This review article has been written to through some light on the recent work that has already been done, to strengthen the role of LF in neonatal sepsis and the work that is still under process.

show abstract

“…Fischer et al (2007) studied the uptake of ingested bLF and its pattern of tissue accumulation in adult mice; immunoreactive bLF is absorbed by the mature mouse intestine. Bovine lactoferrin is transferred from the intestine into the blood circulation and subsequently distributed over various tissues of the mouse such as liver, kidney and spleen.…”

Section: Absorption Distribution Metabolism Excretionmentioning

confidence: 99%

“…Moreover, orally administered bLF was found in the liver, kidneys, gall bladder, spleen and brain of adult mice (Fischer et al, 2007) detected using an ELISA. The Panel considers that the provided studies show absorption of bLF in the intestine in rats, and that rats, therefore, are suitable to study bLF toxicity.…”

Section: Absorption Distribution Metabolism Excretionmentioning

confidence: 99%

“…In addition to an age-related increase in the expression of lactoferrin in brain cells, an increased exogenous supply could also be of relevance. In animal experiments, orally administered bLF has been found as native protein in the brain, inter alia (Fischer et al, 2007;Kamemori et al, 2008). The possibility that lactoferrin is actively involved in neurodegenerative processes cannot be ruled out.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Scientific Opinion on bovine lactoferrin

Products¹

2012

EFSA Journal

View full text Add to dashboard Cite

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to carry out the additional assessment of "lactoferrin" as a food ingredient in the context of Regulation (EC) No 258/97 taking into account the comments and objections of a scientific nature raised by Member States. Bovine lactoferrin (bLF) is a protein that occurs naturally in cow"s milk. The applicant intends to market bLF as an ingredient for food supplements, infant and follow-on formulae, dietetic food for special medical purposes and sports nutrition, and for a variety of foods. For infants with an age of 0 -6 months, the applicant has estimated an intake of approximately 200 mg per kg bodyweight and 1.2 g bLF per day at the proposed use level. For adults, the mean and 95 th percentile daily intakes were calculated to be about 1.4 g and 3.4 g for an adult person. The toxicological information provided by the applicant included information from an in vitro genotoxicity study, a single dose study, a four week and a thirteen week oral repeated dose study in rats. The Panel notes that the estimated intake of "lactoferrin" for infants up to the age of one year of approximately 210 mg/kg bw per day would be around ten times lower than the highest dose (2,000 mg/kg bw per day) tested in the subchronic thirteen week rat study, which did not show adverse effects related to bLF. For adults above 19 years of age the proposed intake is approximately 100 times lower. This level of anticipated intake is considered a high intake scenario as opposed to a worst-case situation. The data provided suggest the absence of adverse effects of lactoferrin at the proposed levels of consumption. The Panel concludes that the novel food ingredient bLF is safe under the proposed uses and use levels. © European Food Safety Authority, 2012 KEY WORDSBovine lactoferrin, novel food, ingredient Bovine lactoferrin (bLF) is a protein that occurs naturally in cow"s milk. The applicant intends to market bLF in isolated and purified form. bLF is an iron-binding glycoprotein of approximately 77 kDa and consists of a single polypeptide chain of about 700 amino acids. The sequence homology between human and bLF is about 70 %. The tertiary structure of this glycoprotein has two ironbinding sites, giving it the capability to bind two Fe 3+ ions per molecule of protein. Batch testing confirmed that the product complies with the given specifications. bLF from skimmed milk is concentrated via ion exchange and is subsequently subjected to filtration steps. Ultimately the bLF is dried by means of spray drying. The applicant provided sufficient information regarding the specification, manufacture, composition and stability of bLF.The applicant intends to market bLF as an ingredient for food supplements, infant and follow-on formulae, dietetic food for special medical purposes and sports nutrition, and for foods such as nonalcoholic beverages, cakes and pastries, products derived from cheese, milk-based products, cold snacks...

show abstract

Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues

Cited by 80 publications

References 39 publications

Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice

Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice

Lactoferrin and Its Role in Neonatology: A Review Article

Scientific Opinion on bovine lactoferrin

Contact Info

Product

Resources

About